Phase II Efficacy and Pharmacogenomic Study of Selumetinib (AZD6244; ARRY-142886) in Iodine-131 Refractory Papillary Thyroid Carcinoma with or without Follicular Elements

PURPOSE: A multicenter, open-label, phase II trial was conducted to evaluate the efficacy, safety, and tolerability of selumetinib in iodine-refractory papillary thyroid cancer (IRPTC). EXPERIMENTAL DESIGN: Patients with advanced IRPTC with or without follicular elements and documented disease progr...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Clin Cancer Res
Egile Nagusiak: Hayes, D. Neil, Lucas, Amy S., Tanvetyanon, Tawee, Krzyzanowska, Monika K., Chung, Christine H., Murphy, Barbara A., Gilbert, Jill, Mehra, Ranee, Moore, Dominic T., Sheikh, Arif, Hoskins, Janelle, Hayward, Michele C., Zhao, Ni, O’Connor, Wendi, Weck, Karen E., Cohen, Roger B., Cohen, Ezra E.W.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2012
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5157199/
https://ncbi.nlm.nih.gov/pubmed/22241789
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-11-0563
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak